225AC-PSMA-617-A New Beginning In The Treatment Of Chemotherapy Naïve Prostate Cancer Patients


 

Prostate Cancer, according to the World Cancer Research Fund, is not only one of the most common malignancy in men, but also one of the most commonly occurring cancer overall. The incidence of prostate cancer increases proportionally with age, especially in men above 60 years of age.

For advanced prostate cancer patients or metastatic castration-resistant prostate cancer (mCRPC) patients, conventional treatment modalities, such as surgery, chemotherapy etc. might not prove to be highly effective in terms of controlling the spread of the cancer. This is where Nuclear Medicine and Molecular Imaging are playing an important part in the management of cancer and that too in a personalized manner.

Several nuclear medicine clinics around world have confirmed that there is now a new hope for metastatic castrate-resistant prostate cancer (mCRPC) patients – Targeted Alpha Therapy of Alpha PSMA Therapy using radiolabeled PSMA inhibitors or alpha-emitting radioisotopes, such as 225Ac.

A NEW BEGINNING:

The treatment of metastatic castrate-resistant prostate cancer (mCRPC) using chemotherapy agents of often short-lived and also incomplete. The over-expression of prostate-specific membrane antigen (PSMA) in metastatic prostate cancer patients has proven to be a suitable target for imaging and therapy. Moreover, the 225Ac labeled derivative – 225Ac-PSMA-617, has shown remarkable therapeutic efficacy, especially in metastatic castrate-resistant prostate cancer (mCRPC) patients. And this was visible in a recently concluded study with a treatment group that comprised patients who relapsed after the initial therapy and presented with metastatic prostate carcinoma – 224Ac-PSMA-617 is definitely more effective for chemotherapy naïve metastatic castrate-resistant prostate cancer (mCRPC) patients.

While the treatment of metastatic castrate-resistant prostate cancer (mCRPC) is still evolving, this study has definitely marked a new beginning in the cancer’s treatment.

WHAT IS ALPHA PSMA THERAPY?

Alpha PSMA Therapy, to put in simpler terms, is a selective and targeted internal medicine cellular level radiotherapy that is administered to control advanced prostate and prostate cancer. The therapy uses alpha-emitting radioisotopes, such as 225Ac to control the cancer. It is completely safe and an effective therapy with minimal side effects. 

ALPHA PSMA THERAPY USING 225Ac-PSMA-617 AT FORTIS MEMORIAL RESEARCH INSTITUTE (FMRI):

Fortis Memorial Research Institute’s Department of Nuclear Medicine and Molecular Imaging has been the pioneer of Targeted Alpha PSMA Therapy both in India and Asia as well. The centre is currently the only centre that offers this therapy in India and has completed 50 treatment cycles. The team of doctors at the centre is extremely excited with the initial results of each therapy cycle where post therapy, most of the patients have experienced a remarkable improvement in their quality of life because of reduced symptoms and pain. Apart from this, an associated biochemical response with a fall in serum PSA levels was observed that indicates reduced tumor burden in the body. Actually, most of the patients have also shown a prolonged duration of response with some of them being in near-complete biochemical and clinical remission for over a year.

Read more at 225AC-PSMA-617-A New Beginning In The Treatment Of Chemotherapy Naïve Prostate Cancer Patients

Comments

Post a Comment

Popular posts from this blog

where is use Yttrium-90 and Its Side Effect

  Yttrium-90 or Y-90 is a commonly used isotope in the medical field specially in departments like nuclear medicine and radiation oncology for radiation therapy. This radioisotope is relied upon to provide a prescribed amount of radiation to a targeted area , such as a tumor. One of the most common uses of Y90 is during an internal radiation therapy called radioembolization. Radioembolization or  Transarterial Radioembolization  using Y-90 involves the use of glass/ resin spheres that are filled with the isotope and placed directly into the blood supply of the liver tumor through a minimally invasive procedure. These spheres get lodged within the tumor itself. The doctors then block off the blood vessels to prevent blood flow (embolization). These Y-90 labelled spheres then get to work by radiating and destroying the tumor. Commonly, Y-90 labelled spheres are used for the treatment of liver tumors, primary hepatocellular carcinoma (HCC) and unresectable primary colore...
Read more

Tare Vs Tace For Hepatocellular Carcinoma and Net Patients

  The incidence of Hepatocellular Carcinoma or HCC has been increasing over the past several years and several studies have projected that the incidence of HCC will continue to rise in the coming years. Transarterial Chemoembolisation or TACE has been the initial treatment modality for HCC and has a huge body of evidence from several studies and clinical trials. Therefore, for long TACE has been a preferred treatment algorithm for unresectable HCC. However, as the experience of  Transarterial Radioembolisation or TARE  has evolved, it is playing an increasingly important role in the treatment of unrespectable HCC. Studies and trials have shown that TARE has many potential advantages over TACE and there is now substantial evidence to favor TARE over TACE. The many potential advantages of TARE when compared with TACE are as below: · Several studies have shown a statistically significant overall survival advantage with TARE as compared to TACE. · TARE has better health-relat...
Read more

Is PRRT Right For You?

Image
  How do doctors determine that PRRT should be the treatment of choice for a neuroendocrine tumour? PRRT  or Peptide Receptor Radionuclide Therapy is a molecular therapy that is one of the accepted modes of treatment for Neuroendocrine Tumours (NETs). Before we go on to discuss the above topic at hand, let me explain PRRT. In PRRT, a radiopeptide is created by combining a small amount of radioactive material or radionuclide (Yttrium-90 or Y-90 and Lutetium-177 or Lu-77) with a cell-targeting protein. This radiopeptide, when injected into a neuroendocrine tumour patient’s bloodstream, travels and binds itself to the neuroendocrine tumour cells to deliver a high dose of radiation that targets only the cancer cells. Also Read:  How Does a Typical PRRT Day look like? Doctors recommend PRRT for patients diagnosed with Advanced Metastatic or Progressive Neuroendocrine Tumours (NETs); also for NET patients who are ineligible for surgery; and also for those NET patients w...
Read more